Evidence vs. Efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany

被引：0

作者：

Brehler R. ^{[1
]}

Klimek L. ^{[2
]}

Vogelberg C. ^{[3
]}

Werfel T. ^{[4
]}

Pfaar O. ^{[2
,5
]}

Hamelmann E. ^{[6
,7
]}

机构：

[1] Outpatient Allergology Clinic, Occupational Dermatology and Environmental Medicine, Department of Dermatology, Münster University Hospital, Münster

[2] Center for Rhinology and Allergology, Wiesbaden

[3] Department of Pediatrics and Adolescent Medicine, Carl Gustav Carus University Hospital, Dresden

[4] Department of Dermatology, Venereology, and Allergology, Hannover Medical University, Hannover

[5] ENT at Mannheim University Hospital, Mannheim

[6] Ruhr Allergy Center, Ruhr University Bochum

[7] Bethel Pediatric Center, Bielefeld

来源：

Allergo Journal International | 2016年 / 25卷 / 2期

关键词：

Allergic rhinoconjunctivitis; Allergology; Efficacy; Evidence; Guideline; Hypersensitization;

D O I：

10.1007/s40629-016-0096-2

中图分类号：

学科分类号：

摘要：

The recently published S2k-guideline on (allergen-) specific immunotherapy (AIT) provides an excellent overview of the evidence on allergen preparations available for AIT in Germany based on the published efficacy studies. Publications based on the guideline are currently being used by the German associations of statutory health insurance physicians and German health insurance funds to open a discussion on the reimbursement status of allergen preparations. In our view, calling the reimbursement status of perscribable and tradable AIT preparations into question on the basis of an assessment of the current body of evidence in the guideline is to be rigidly opposed. In Germany the Paul Ehrlich Institute (PEI) is the only authority empowered to decide on the marketability of AIT preparations, and decisions on the reimbursement status of AIT products need to be based on cost– benefit analyses and not solely on an evaluation of the evidence. The present article aims to examine the relationship between the evidence, efficacy, tradability, and reimbursability of AIT preparations. © 2016, Springer Medizin. All rights reserved.

引用

页码：38 / 43

页数：5

共 8 条

[1] Akdis M., Akdis C.A., Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens, J Allergy Clin Immunol, 133, pp. 621-631, (2014)
[2] Abramson M.J., Puy R.M., Weiner J.M., Injection allergen immunotherapy for asthma, Cochrane Database Syst Rev, 8, (2010)
[3] Burks A.W., Calderon M.A., Casale T., Cox L., Demoly P., Jutel M., Et al., Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report, J Allergy Clin Immunol, 131, pp. 1288-1296, (2013)
[4] Pfaar O., Bachert C., Bufe A., Buhl R., Ebner C., Eng P., Et al., Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases – S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology
[5] Canonica G.W., Baena-Cagnani C.E., Bousquet J., Bousquet P.J., Lockey R.F., Malling H.J., Et al., Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce, Allergy, 62, pp. 317-324, (2007)
[6] Pfaar O., Demoly P., Gerth van Wijk R., Bonini S., Bousquet J., Canonica G.W., Et al., European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper, Allergy, 69, pp. 854-867, (2014)
[7] Englert L., May S., Kaul S., Vieths S., The therapy allergens ordinance („Therapieallergene-Verordnung“). Background and effects, Bundesgesundheitsbl Gesundheits-Forsch Gesundheitsschutz, 55, pp. 351-357, (2012)
[8] Bachert C., Überarbeitete S2k-Leitlinie zur (Allergen-)spezi-fischen Immuntherapie, Allergologie, 38, pp. 178-180, (2015)

← 1 →